These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20926483)

  • 1. Rosiglitazone and the need for a new drug safety agency.
    Garattini S; Bertele' V
    BMJ; 2010 Oct; 341():c5506. PubMed ID: 20926483
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosiglitazone: what went wrong?
    Cohen D
    BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
    [No Abstract]   [Full Text] [Related]  

  • 3. Licensing drugs for diabetes.
    Lehman R; Yudkin JS; Krumholz H
    BMJ; 2010 Sep; 341():c4805. PubMed ID: 20819887
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
    Freemantle N
    BMJ; 2010 Sep; 341():c4812. PubMed ID: 20819888
    [No Abstract]   [Full Text] [Related]  

  • 5. European regulatory body recommends suspension of rosiglitazone.
    Cohen D
    BMJ; 2010 Sep; 341():c5291. PubMed ID: 20870700
    [No Abstract]   [Full Text] [Related]  

  • 6. Insiders criticise FDA's decision not to withdraw rosiglitazone.
    Cohen D
    BMJ; 2010 Sep; 341():c5333. PubMed ID: 20880925
    [No Abstract]   [Full Text] [Related]  

  • 7. Playing the numbers game.
    Drug Ther Bull; 2011 Jan; 49(1):1. PubMed ID: 21220251
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA puts rosiglitazone post-marketing trial on hold.
    Cohen D
    BMJ; 2010 Jul; 341():c4017. PubMed ID: 20660507
    [No Abstract]   [Full Text] [Related]  

  • 9. European drug regulators publish their evaluation of rosiglitazone.
    Mayor S
    BMJ; 2010 Dec; 341():c7278. PubMed ID: 21169326
    [No Abstract]   [Full Text] [Related]  

  • 10. Data openness. Independent public inquiries needed to ensure drug safety.
    Edwards B
    BMJ; 2010 Nov; 341():c6336. PubMed ID: 21081612
    [No Abstract]   [Full Text] [Related]  

  • 11. [Suspension of the commercialization of sibutramine and rosiglitazone in Europe].
    Scheen AJ
    Rev Med Liege; 2010 Oct; 65(10):574-9. PubMed ID: 21128363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone, marketing, and medical science.
    Moynihan R
    BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
    [No Abstract]   [Full Text] [Related]  

  • 13. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
    Rosen CJ
    N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical consequences of disseminating the rosiglitazone FDA safety warning.
    Orrico KB; Lin JK; Wei A; Yue H
    Am J Manag Care; 2010 May; 16(5):e111-6. PubMed ID: 20455636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA places greater restrictions on access to rosiglitazone.
    BMJ; 2010 Sep; 341():c5287. PubMed ID: 20870699
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA committees say keep rosiglitazone available but increase warnings.
    Tanne JH
    BMJ; 2007 Aug; 335(7613):223. PubMed ID: 17673743
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA advisers recommend new controls on rosiglitazone use.
    Traynor K
    Am J Health Syst Pharm; 2010 Aug; 67(16):1306-8. PubMed ID: 20689113
    [No Abstract]   [Full Text] [Related]  

  • 18. [Wrong choice of antidiabetics can be disastrous].
    Sjöholm A
    Lakartidningen; 2010 Sep 29-Oct 5; 107(39):2300-1. PubMed ID: 20973243
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosiglitazone: trials, tribulations and termination.
    Krentz AJ
    Drugs; 2011 Jan; 71(2):123-30. PubMed ID: 21275442
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA hearings leave doctors, patients in limbo on Avandia.
    Eggertson L; Woodward C
    CMAJ; 2010 Sep; 182(12):E559-60. PubMed ID: 20660583
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.